[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628926":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":24,"centralContacts":27,"locations":35,"responsibleParty":170,"collaborators":24,"id":172,"slug":173,"hasResults":174,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":174,"sex":180,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":24,"studyType":186,"phases":187,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":38,"whyStopped":24,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GXV813","EXPERIMENTAL","GXV813 administered orally.",[13],"Drug: GXV813",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo administered orally.",[19],"Drug: Placebo",[21,25],{"type":22,"name":9,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG",[9],null,{"type":22,"name":15,"description":17,"armGroupLabels":26,"otherNames":24},[15],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":24,"email":32},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":29,"role":30,"phone":34,"phoneExt":24,"email":24},"+41613241111",[36,54,67,80,93,106,114,127,138,146,154,162],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Pillar Clinical Research LLC","RECRUITING","Bentonville","Arkansas","72712","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-94.20882,36.37285,{"lat":48,"lon":47},[51],{"name":52,"role":53,"phone":24,"phoneExt":24,"email":24},"Leslie Smith","PRINCIPAL_INVESTIGATOR",{"facility":55,"status":38,"city":56,"state":57,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"CNRI Los Angeles LLC","Pico Rivera","California","90660",{"type":45,"coordinates":60},[61,62],-118.09673,33.98307,{"lat":62,"lon":61},[65],{"name":66,"role":53,"phone":24,"phoneExt":24,"email":24},"Mohamed El-Gabalawy",{"facility":68,"status":38,"city":69,"state":70,"zip":71,"country":42,"countryCode":43,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Segal Institute for Clinical Research","Miami","Florida","33016",{"type":45,"coordinates":73},[74,75],-80.19366,25.77427,{"lat":75,"lon":74},[78],{"name":79,"role":53,"phone":24,"phoneExt":24,"email":24},"Rishi Kakar",{"facility":81,"status":38,"city":82,"state":83,"zip":84,"country":42,"countryCode":43,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"CenExel iResearch","Decatur","Georgia","30030",{"type":45,"coordinates":86},[87,88],-84.29631,33.77483,{"lat":88,"lon":87},[91],{"name":92,"role":53,"phone":24,"phoneExt":24,"email":24},"Kimball Johnson",{"facility":94,"status":38,"city":95,"state":96,"zip":97,"country":42,"countryCode":43,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Uptown Research Institute LLC","Chicago","Illinois","60640",{"type":45,"coordinates":99},[100,101],-87.65005,41.85003,{"lat":101,"lon":100},[104],{"name":105,"role":53,"phone":24,"phoneExt":24,"email":24},"John Sonnenberg",{"facility":37,"status":38,"city":95,"state":96,"zip":107,"country":42,"countryCode":43,"cosmosGeoPoint":108,"geoPoint":110,"contacts":111},"60641",{"type":45,"coordinates":109},[100,101],{"lat":101,"lon":100},[112],{"name":113,"role":53,"phone":24,"phoneExt":24,"email":24},"Scott Bartley",{"facility":115,"status":38,"city":116,"state":117,"zip":118,"country":42,"countryCode":43,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Arch Clinical Trials LLC","St Louis","Missouri","63141",{"type":45,"coordinates":120},[121,122],-90.19789,38.62727,{"lat":122,"lon":121},[125],{"name":126,"role":53,"phone":24,"phoneExt":24,"email":24},"Syed Junaid",{"facility":128,"status":38,"city":129,"state":130,"zip":131,"country":130,"countryCode":132,"cosmosGeoPoint":133,"geoPoint":137,"contacts":24},"Novartis Investigative Site","Kazanlak","Bulgaria","6100","BG",{"type":45,"coordinates":134},[135,136],25.4,42.61667,{"lat":136,"lon":135},{"facility":128,"status":38,"city":139,"state":24,"zip":140,"country":130,"countryCode":132,"cosmosGeoPoint":141,"geoPoint":145,"contacts":24},"Lovech","5500",{"type":45,"coordinates":142},[143,144],24.71763,43.13227,{"lat":144,"lon":143},{"facility":128,"status":38,"city":147,"state":24,"zip":148,"country":130,"countryCode":132,"cosmosGeoPoint":149,"geoPoint":153,"contacts":24},"Sofia","1377",{"type":45,"coordinates":150},[151,152],23.32415,42.69751,{"lat":152,"lon":151},{"facility":128,"status":38,"city":155,"state":24,"zip":156,"country":130,"countryCode":132,"cosmosGeoPoint":157,"geoPoint":161,"contacts":24},"Veliko Tarnovo","5000",{"type":45,"coordinates":158},[159,160],25.62904,43.08124,{"lat":160,"lon":159},{"facility":128,"status":38,"city":163,"state":24,"zip":164,"country":130,"countryCode":132,"cosmosGeoPoint":165,"geoPoint":169,"contacts":24},"Vratsa","3000",{"type":45,"coordinates":166},[167,168],23.56312,43.21052,{"lat":168,"lon":167},{"type":171,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100628926","phase-2-study-to-assess-the-safety-tolerability-and-treatment-response-of-gxv813-in-hospitalized-adults-with-schizophrenia-100628926",false,"NCT07467993","Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia","A Phase 2a, Randomized, Participant- and Investigator- Blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With DSM-5 Schizophrenia (STAR-1)","STAR-1","Inclusion Criteria:\n\n1. Participant is aged 18 to 65 years, inclusive, at screening\n2. Participant is capable of providing informed consent\n3. Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)\n4. Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements\n5. Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening\n\n   1. The participant requires hospitalization for this acute exacerbation or relapse of symptoms\n   2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening\n6. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items:\n\n   i. Item 1 (P1; delusions)\n\nii. Item 2 (P2; conceptual disorganization)\n\niii. Item 3 (P3; hallucinatory behavior)\n\niv. Item 6 (P6; suspiciousness\u002Fpersecution)\n\nExclusion Criteria:\n\n1. Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)\n2. History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia\n3. Participants who need to be treated with drugs that are known to be moderate and strong CYP3A4 inhibitors and inducers will be excluded\n4. Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","65 Years",{"count":184,"type":185},142,"ESTIMATED","INTERVENTIONAL",[188],"PHASE2","The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia",[191],"Schizophrenia",[191,193],"GVX813","2026-06-25",{"date":196,"type":197},"2026-06-26","ACTUAL",{"date":199,"type":197},"2026-03-16",{"date":201,"type":185},"2027-07-29",{"name":29,"class":6},12]